We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aravive Biologics

News List

Aravive Biologics Achieves Proof-of-Mechanism for Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500, in Ongoing Phase 1 Trial pharmafocusasia
May 14, 2018
Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study (32 subjects).
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Success prnasia
January 31, 2018
WuXi Biologics today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-50